Generated by Rank Math SEO, this is an llms.txt file designed to help LLMs better understand and index this website.

# 漢康生技股份有限公司

## Sitemaps
[XML Sitemap](https://www.hanchorbio.com/sitemap_index.xml): Includes all crawlable and indexable pages.

## 頁面
- [聯絡我們](https://www.hanchorbio.com/contact/)
- [產品管線](https://www.hanchorbio.com/pipeline/)
- [新藥研發介紹](https://www.hanchorbio.com/new-drug/)
- [隱私權條款](https://www.hanchorbio.com/privacy/)
- [核心技術](https://www.hanchorbio.com/core-technologies/)
- [加入漢康](https://www.hanchorbio.com/careers/)
- [關於漢康](https://www.hanchorbio.com/about/)
- [首頁](https://www.hanchorbio.com/)

## 利害關係人專區
- [利害關係人溝通](https://www.hanchorbio.com/stakeholders/%e5%88%a9%e5%ae%b3%e9%97%9c%e4%bf%82%e4%ba%ba%e6%ba%9d%e9%80%9a/)
- [漢康利害關係人鑑別](https://www.hanchorbio.com/stakeholders/%e6%bc%a2%e5%ba%b7%e5%88%a9%e5%ae%b3%e9%97%9c%e4%bf%82%e4%ba%ba/)

## 投資人專區
- [股東專區](https://www.hanchorbio.com/investors/shareholders/)
- [組織架構](https://www.hanchorbio.com/investors/shareholders/structure/)
- [公司治理](https://www.hanchorbio.com/investors/shareholders/governance/)
- [董事及董事會](https://www.hanchorbio.com/investors/shareholders/board/)
- [股權結構](https://www.hanchorbio.com/investors/shareholders/%e8%82%a1%e6%ac%8a%e7%b5%90%e6%a7%8b/)
- [法說會](https://www.hanchorbio.com/investors/shareholders/briefing/)
- [股東會](https://www.hanchorbio.com/investors/shareholders/meeting/)
- [功能性委員會](https://www.hanchorbio.com/investors/shareholders/%e5%8a%9f%e8%83%bd%e6%80%a7%e5%a7%94%e5%93%a1%e6%9c%83/)
- [電子書](https://www.hanchorbio.com/investors/financials/)
- [電子書](https://www.hanchorbio.com/investors/financials/reports/)
- [投資問與答](https://www.hanchorbio.com/investors/faq/)

## 最新消息
- [漢康生技召開科學顧問委員會議　HCB101 臨床進展與 FDA 共識支持邁向全球註冊性臨床開發 HanchorBio Advances HCB101 Toward Global Registrational Development Following SAB Review and FDA Alignment](https://www.hanchorbio.com/news/hanchorbio-advances-hcb101-toward-global-registrational-development-following-sab-review-and-fda-alignment/): HanchorBio announced outcomes from its latest Scientific Advisory Board (SAB) meeting. Highlights included significant clinical progress for its lead asset, HCB101; alignment with the U.S. FDA on a registrational pathway in second-line gastric/ gastroesophageal junction (GC/GEJ) cancer; and continued expansion of the company’s research pipeline across oncology and immune-mediated diseases.
- [漢康生技擴大 HCB101 於台灣大腸直腸癌臨床開發 二線治療初步數據顯示 ORR 達 50%、DCR 達 100% HanchorBio Expands HCB101 Colorectal Cancer Program in Taiwan  as Early 2L CRC Data Show 50% ORR and 100% DCR](https://www.hanchorbio.com/news/hanchorbio-expands-hcb101-colorectal-cancer-program-in-taiwan-as-early-2l-crc-data-show-50-orr-and-100-dcr/): HanchorBio today announced that the first patient in Taiwan has been dosed in the colorectal cancer (CRC)-specific cohort of its global Phase 1b/2a HCB101-201 study (NCT06771622), expanding the Company’s global development program in second-line metastatic CRC.
- [漢康生技參展BioJapan 2026 深化日本市場拓展並推進全球合作機會 HanchorBio Expands Global Pharma Engagement at BioJapan 2026](https://www.hanchorbio.com/news/hanchorbio-expands-global-pharma-engagement-at-biojapan-2026/): HanchorBio announced its participation in BioJapan 2026 in Yokohama, Japan. The Company has scheduled more than 15 partnering meetings with regional and global pharmaceutical leaders to explore co-development and strategic collaboration opportunities across its proprietary Fc-based Designer Biologics (FBDB™) platform.
- [漢康-KY向TFDA提交 HCB303 IND 申請　推進三特異性免疫療法全球臨床開發 HanchorBio Advances HCB303 Global Clinical Development with Taiwan TFDA IND Submission Following US FDA Clearance](https://www.hanchorbio.com/news/hanchorbio-advances-hcb303-global-clinical-development-with-taiwan-tfda-ind-submission-following-us-fda-clearance/): HanchorBio announced the submission of an Investigational New Drug (IND) to the Taiwan Food and Drug Administration (TFDA) for HCB303.
- [漢康-KY宣布 HCB303 IND 獲美國 FDA 同意　新一代三特異性免疫療法邁入臨床開發 HanchorBio Announces U.S. FDA Clearance of IND Application for HCB303, a Next-Generation Trispecific Immunotherapy](https://www.hanchorbio.com/news/hanchorbio-announces-u-s-fda-clearance-of-ind-application-for-hcb303-a-next-generation-trispecific-immunotherapy/): HanchorBio announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for HCB303. The clearance enables HanchorBio to initiate its Phase 1 first-in-human clinical trial.
- [漢康-KY第二屆技術研發日揭示全球成長策略與多元產品線布局 HanchorBio Outlines Global Growth Strategy and Multi-Asset Pipeline at Second Annual R&D Day](https://www.hanchorbio.com/news/hanchorbio-outlines-global-growth-strategy-and-multi-asset-pipeline-at-second-annual-rd-day/): HanchorBio hosted its second R&D Day. The Company presented its evolution from a single-asset clinical validation model into a multi-asset, macrophage-directed immunotherapy platform with global commercial potential.
- [漢康生技五項臨床研究入選 CSCO 2026 HanchorBio to Present Five Clinical Abstracts at CSCO 2026](https://www.hanchorbio.com/news/csco-2026-hanchorbio-to-present-five-clinical-abstracts-at-csco-2026/): HanchorBio announced that five company-sponsored clinical abstracts have been accepted for presentation at the 29th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO 2026).
- [漢康生技攜手 InSilicoTrials 推進 HCB101 AI 驅動臨床開發 HanchorBio Partners with InSilicoTrials to Advance AI-Driven Clinical Development for HCB101](https://www.hanchorbio.com/news/hanchorbio-partners-with-insilicotrials-to-advance-ai-driven-clinical-development-for-hcb101/): HanchorBio announced that it has entered into a strategic memorandum of understanding (MOU) and an initial statement of work with InSilicoTrials Technologies S.p.A.
- [漢康生技將於 BioCon China Expo 2026 分享巨噬細胞增強平台與免疫治療布局 HanchorBio Advances Its Myeloid Enhancer Platform at BioCon China Expo 2026](https://www.hanchorbio.com/news/hanchorbio-advances-its-myeloid-enhancer-platform-at-biocon-china-expo-2026/): HanchorBio announced that Founder and Chairman Dr. Scott Liu will present at BioCon China Expo 2026 on September 15.
- [漢康生技 HCB101 達成臨床開發里程碑　美FDA 同意單一病人擴大使用（恩慈使用） HanchorBio Reaches Clinical Milestone for HCB101 as US FDA Allows Continued Treatment for Phase 1 Patient Experiencing Clinical Benefit](https://www.hanchorbio.com/news/hanchorbio-reaches-clinical-milestone-for-hcb101-as-us-fda-allows-continued-treatment-for-phase-1-patient-experiencing-clinical-benefit/): HanchorBio announced that the U.S. Food and Drug Administration (FDA) has cleared its HCB101 Single-Patient Expanded Access Protocol (HCB101- EA-001) as “safe to proceed”.
- [漢康-KY受邀出席統一證券秋季投資論壇　分享臨床開發、產品布局與全球化策略 HanchorBio Highlights Clinical, Pipeline, and Global Growth Strategy](https://www.hanchorbio.com/news/hanchorbio-highlights-clinical-pipeline-and-global-growth-strategy/): HanchorBio highlighted its clinical development, pipeline expansion, and global growth strategy following a presentation at the “2026 Q3 Global Outlook Autumn Investment Forum” hosted by President Securities at Grand Hyatt Taipei.
- [漢康生技 HCB101 與 HCB301 雙獲 KSMO/FACO 2026 肯定 HanchorBio Earns Dual KSMO/FACO 2026 Recognition for HCB101 and HCB301](https://www.hanchorbio.com/news/hanchorbio-earns-dual-ksmo-faco-2026-recognition-for-hcb101-and-hcb301/): HanchorBio announced clinical results from HCB101 and HCB301 presented at KSMO 2026—the 19th Annual Meeting of the Korean Society of Medical Oncology and 2026 International Conference—held in conjunction with the 14th International Conference of the Federation of Asian Clinical Oncology (FACO), in Seoul, South Korea.
- [漢康-KY向美國 FDA 提交 HCB303 IND 申請　第二款三特異性免疫療法邁向臨床開發 HanchorBio Files U.S. IND for Second Trispecific Immunotherapy, HCB303](https://www.hanchorbio.com/news/hanchorbio-files-u-s-ind-for-second-trispecific-immunotherapy-hcb303/): HanchorBio announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for HCB303. Developed using HanchorBio’s proprietary FBDB™ platform, HCB303 is the Company’s second trispecific immunotherapy program to reach clinical development.
- [漢康生技將於 2026 Jefferies亞太醫療健康大會分享產品線策略 HanchorBio to Present Pipeline Strategy at 2026 Jefferies APAC Healthcare Conference](https://www.hanchorbio.com/news/hanchorbio-to-present-pipeline-strategy-at-2026-jefferies-apac-healthcare-conference/): HanchorBio announced that executive management will participate in the 2026 Jefferies APAC Healthcare Conference, taking place September 20–21, 2026, at Hilton Shanghai Zhangjiang Science Park in Shanghai.
- [漢康-KY受邀於臨床試驗論壇分享胃癌免疫治療全球開發策略　HCB101邁向第一期臨床後新階段 HanchorBio Outlines Global Strategy for Gastric Cancer Immunotherapy as HCB101 Advances Beyond Phase 1](https://www.hanchorbio.com/news/hanchorbio-outlines-global-strategy-for-gastric-cancer-immunotherapy-as-hcb101-advances-beyond-phase-1/): HanchorBio announced that Alvin Luk, PhD, MBA, CCRA, President and Chief Medical Officer (Group) and CEO (USA) of HanchorBio, presented the Company’s vision for the next phase of gastric cancer immunotherapy at the Early Phase Clinical Trials: Innovation and Precision Medicine Forum in Taichung, Taiwan.
- [漢康-KY受邀於產業論壇分享髓系細胞導向治療策略　HCB101臨床進展支持FBDB™平台拓展至腫瘤以外疾病領域 HanchorBio Advances Myeloid-Directed Therapeutics Strategy Beyond Oncology with HCB101 Clinical Progress and FBDB™ Platform Expansion](https://www.hanchorbio.com/news/hanchorbio-advances-myeloid-directed-therapeutics-strategy-beyond-oncology-with-hcb101-clinical-progress-and-fbdb-platform-expansion/): HanchorBio shared its latest clinical and research progress in myeloid-directed therapeutics at the 2026 Autumn Industry Trends and Corporate Forum hosted by Hua Nan Securities. The Company presented its development strategy centered on the proprietary FBDB™ multifunctional biologics platform and myeloid enhancer approach, highlighting clinical progress of HCB101 in solid tumors and the expansion of macrophage-directed biology into HCB206 for immune-mediated diseases.
- [漢康生技擴展次世代免疫治療策略　整合免疫教育與巨噬細胞活化 HanchorBio Expands Next-Generation Immunotherapy Strategy by Integrating Immune Education and Macrophage Activation](https://www.hanchorbio.com/news/hanchorbio-expands-next-generation-immunotherapy-strategy-by-integrating-immune-education-and-macrophage-activation/): HanchorBio announced the expansion of its immunotherapy strategy to explore vaccine-based immune activation approaches through strategic collaborations in cancer and immune-mediated diseases.
- [漢康生技 HCB301 獲選 KSMO 2026 口頭報告　HCB101 胃癌研究榮獲最佳海報發表獎 HanchorBio Announces HCB301 Oral Presentation and HCB101 Best Poster Selection at KSMO 2026](https://www.hanchorbio.com/news/hanchorbio-announces-hcb301-oral-presentation-and-hcb101-best-poster-selection-at-ksmo-2026/): HanchorBio announced that three abstracts featuring its clinical-stage programs HCB101 and HCB301 have been accepted for presentation at KSMO 2026—the 19th Annual Meeting of the Korean Society of Medical Oncology and 2026 International Conference—held in conjunction with the 14th International Conference of the Federation of Asian Clinical Oncology (FACO), taking place September 2–4, 2026, in Seoul, Korea.
- [漢康生技推進巨噬細胞導向免疫治療策略 HCB101 全球頭頸癌研究完成首位病人給藥 HanchorBio Advances HCB101 Macrophage-Directed Immunotherapy Strategy with First Patient Dosed in Global HNSCC Study](https://www.hanchorbio.com/news/hanchorbio-advances-hcb101-macrophage-directed-immunotherapy-strategy-with-first-patient-dosed-in-global-hnscc-study/): HanchorBio announced that the first patient has been dosed in Cohort 6b of its global Phase 1b/2a HCB101-201 study
- [漢康生技取得美國 FDA Pre-IND 回覆 支持下一代三特異性免疫療法 HCB303 推進開發 HanchorBio Receives FDA Pre-IND Feedback  Supporting Advancement of HCB303, a Next-Generation Trispecific Immunotherapy](https://www.hanchorbio.com/news/hanchorbio-receives-fda-pre-ind-feedback-supporting-advancement-of-hcb303-a-next-generation-trispecific-immunotherapy/): HanchorBio announced that it has received written responses from the U.S. Food and Drug Administration (FDA) following a Type B pre-Investigational New Drug (pre-IND) submission for HCB303, the Company’s next-generation, first-in-class trispecific immunotherapy designed to simultaneously activate innate and adaptive antitumor immunity.
- [從巨噬細胞生物學到臨床開發： 漢康生技推進胃癌免疫治療的未來 From Macrophage Biology to Clinical Development:  HanchorBio Advances the Future of Gastric Cancer Immunotherapy](https://www.hanchorbio.com/news/from-macrophage-biology-to-clinical-development-hanchorbio-advances-the-future-of-gastric-cancer-immunotherapy/): HanchorBio announced insights from the “Taiwan Gastric Cancer Experts Forum on Clinical Challenges and Emerging Immunotherapy”, held August 8–9 in Taichung, Taiwan.
- [漢康-KY子公司與臺灣癌症登月計畫俞松良教授團隊建立戰略合作　共同推進精準腫瘤醫學 HanchorBio and Taiwan Cancer Moonshot Project-NTU Subteam Led by Professor Sung-Liang Yu Establish Strategic Collaboration to Advance Precision Oncology](https://www.hanchorbio.com/news/hanchorbio-and-taiwan-cancer-moonshot-project-ntu-subteam-led-by-professor-sung-liang-yu-establish-strategic-collaboration-to-advance-precision-oncology/): HanchorBio announced that its wholly owned Taiwan subsidiary has entered into a strategic collaboration with the research team led by Professor Sung-Liang Yu of National Taiwan University, a key participating team in the Taiwan Cancer Moonshot Program (TCMP). The collaboration has been formalized through a memorandum of understanding signed by HanchorBio Taiwan and Professor Yu’s team.
- [漢康生技受邀出席第九屆 BPD 生物藥工藝發展大會　分享下一代創新藥製程與 CMC 開發實務 HanchorBio Invited to Present at the 9th BPD Biopharmaceutical Process Development Conference on Next-Generation Drug Manufacturing and CMC Development](https://www.hanchorbio.com/news/hanchorbio-invited-to-present-at-the-9th-bpd-biopharmaceutical-process-development-conference-on-next-generation-drug-manufacturing-and-cmc-development/): HanchorBio announced that Vivian Kuo, PhD, Executive Director of CMC, has been invited to speak at the 2026 9th BPD Biopharmaceutical Process Development Conference.
- [漢康-KY公布主力創新藥最新臨床進展 深化巨噬細胞導向腫瘤治療策略 HanchorBio Expands Clinical Evidence Supporting Its Macrophage-Directed Oncology Strategy](https://www.hanchorbio.com/news/hanchorbio-expands-clinical-evidence-supporting-its-macrophage-directed-oncology-strategy/): HanchorBio announced updated early clinical observations from its HCB101 program.
- [漢康-KY攜「臨床定錨到平台拓展」策略亮相BIO Asia–Taiwan 2026 HanchorBio Brings Clinical Anchor-to-Platform Strategy to BIO Asia–Taiwan 2026](https://www.hanchorbio.com/news/hanchorbio-to-present-fbdb-platform-strategy-and-clinical-pipeline-progress-at-bio-asia-taiwan-2026/): HanchorBio announced that it will present its clinical development and platform strategy at BIO Asia–Taiwan 2026, taking place July 16–19, 2026, in Taipei, Taiwan.
- [漢康-KY與應世生物簽署戰略合作備忘錄，探索HCB101於難治實體瘤之聯合療法策略 HanchorBio and InxMed Sign Strategic MOU to Explore HCB101-Based Combination Therapies for Difficult-to-Treat Solid Tumors](https://www.hanchorbio.com/news/hanchorbio-and-inxmed-sign-strategic-mou-to-explore-hcb101-based-combination-therapies-for-difficult-to-treat-solid-tumors/): HanchorBio announced that its subsidiary, FBD Biologics Limited, has signed a strategic memorandum of understanding (“MOU”) with InxMed (Shanghai) Co., Ltd. (“InxMed”).
- [漢康生技宣布取得 FDA Type C 會議正式紀錄，支持 HCB101 於二線胃癌／胃食管結合部癌之明確開發路徑 HanchorBio Announces FDA Type C Meeting Minutes  Supporting a Clear Development Path for HCB101 in Second-Line Gastric/GEJ Cancer](https://www.hanchorbio.com/news/hanchorbio-announces-fda-type-c-meeting-minutes-supporting-a-clear-development-path-for-hcb101-in-second-line-gastric-gej-cancer/): HanchorBio announced receipt of the official minutes from its recent U.S. Food and Drug Administration (FDA) Type C meeting regarding the post-Phase 1 development strategy for HCB101.
- [漢康生技於 JCA-AACR 2026 發表 HCB101 胃癌及頭頸癌臨床數據，展現髓系免疫增強策略潛力 HanchorBio Showcases HCB101 Myeloid-Enhancer Strategy in Gastric Cancer and HNSCC at JCA-AACR 2026](https://www.hanchorbio.com/news/hanchorbio-showcases-hcb101-myeloid-enhancer-strategy-in-gastric-cancer-and-hnscc-at-jca-aacr-2026/): HanchorBio, Inc. announced poster presentations of HCB101 clinical data at the 9th Japanese Cancer Association (JCA) and the American Association for Cancer Research (AACR) Special Joint Conference on Novel Therapies and Diagnostics in Upper Digestive and Head and Neck Cancers, taking place June 28-30, 2026, in Kyoto, Japan.
- [漢康生技受邀於 TRPMA 生技產業交流講座分享國際化發展經驗](https://www.hanchorbio.com/news/hanchorbio-invited-to-share-international-expansion-experience-at-trpma-biotech-industry-exchange-forum/): HanchorBio Invited to Share International Expansion Experience at TRPMA Biotech Industry Exchange Forum.
- [漢康生技將出席 BIO 國際大會 2026，拓展全球合作交流機會 HanchorBio to Attend BIO International Convention 2026 to Advance Global Partnering Opportunities](https://www.hanchorbio.com/news/hanchorbio-to-attend-bio-international-convention-2026-to-advance-global-partnering-opportunities/): HanchorBio today announced that Dr. Yuehua Cong, Chief Business Officer, will attend BIO International Convention 2026
- [漢康生技於2026 ESMO靶向抗癌治療亞洲大會發表兩場口頭報告，展現下一代免疫療法臨床進展 HanchorBio Presents Two Oral Presentations at ESMO TAT Asia 2026 Highlighting Progress Across Its Next-Generation Immunotherapy Pipeline](https://www.hanchorbio.com/news/hanchorbio-presents-two-oral-presentations-at-esmo-tat-asia-2026-highlighting-progress-across-its-next-generation-immunotherapy-pipeline/): HanchorBio announced that two company-sponsored clinical programs were featured in oral presentations at the European Society for Medical Oncology Targeted Anticancer Therapies Asia Congress 2026, ESMO TAT Asia 2026, held in Hong Kong.
- [漢康生技於 FOCIS 2026 發表突破性數據，支持先天免疫產品引擎布局腫瘤與自體免疫疾病 HanchorBio Presents Late-Breaking Data at FOCIS 2026 Supporting Innate-Immune Product Engine Across Oncology and Autoimmune Disease](https://www.hanchorbio.com/news/hanchorbio-presents-late-breaking-data-at-focis-2026-supporting-innate-immune-product-engine-across-oncology-and-autoimmune-disease/): HanchorBio announced the presentation of late-breaking clinical and translational data at the Federation of Clinical Immunology Societies Annual Meeting, FOCIS 2026, being held June 9-12, 2026, in San Francisco.
- [漢康生技於 ASCO 2026 發表兩項摘要，展現 HCB101 聯合療法臨床活性與 HCB301 首次人體試驗進展 HanchorBio Presents Two ASCO 2026 Abstracts Highlighting HCB101 Combination Activity and HCB301 First-in-Human Clinical Progress](https://www.hanchorbio.com/news/hanchorbio-presents-two-asco-2026-abstracts-highlighting-hcb101-combination-activity-and-hcb301-first-in-human-clinical-progress/): HanchorBio announced updated clinical data for HCB101 and HCB301 presented at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
- [漢康-KY將於5月29日創新板掛牌　HCB101臨床進展帶動國際合作布局 HanchorBio to List on Taiwan Innovation Board at NT$120 per Share as HCB101 Clinical Data Support Global Partnering Discussions](https://www.hanchorbio.com/news/hanchorbio-to-list-on-taiwan-innovation-board-at-nt120-per-share-as-hcb101-clinical-data-support-global-partnering-discussions/): HanchorBio announced that it will be officially listed on the Taiwan Innovation Board on May 29, 2026, with an underwriting price of NT$120 per share.
- [漢康-KY引進國際策略投資人奧博資本入股 5月29日創新板掛牌 詢圈超額認購 HanchorBio Prices IPO at NT$120 Ahead of Innovation Board Listing on May 29](https://www.hanchorbio.com/news/hanchorbio-prices-ipo-at-nt120-ahead-of-innovation-board-listing-on-may-29/): HanchorBio announced the completion of bookbuilding for its initial public offering on the Taiwan Innovation Board. The offering price has been set at NT$120 per share. HanchorBio is expected to list on the Taiwan Innovation Board on May 29, 2026.
- [首筆授權金挹注營收 漢康-KY聚焦2026年臨床與商務發展重點 推進HCB101臨床開發、創新板上市進程及國際合作布局 HanchorBio Reports First Licensing Revenue and Outlines 2026 Clinical and Business Development Priorities](https://www.hanchorbio.com/news/hanchorbio-reports-first-licensing-revenue-and-outlines-2026-clinical-and-business-development-priorities/): HanchorBio today announced that its 2026 Annual General Meeting was successfully held on May 21, 2026, in Taipei, Taiwan. Shareholders approved all proposed resolutions, including the 2025 business report, financial statements, and loss offset proposal.
- [漢康生技宣布 HCB101聯合治療研究之結直腸癌臨床研究觀察到首例部分緩解（PR）HanchorBio Announces First Confirmed Partial Response in Colorectal Cancer Cohort of Ongoing HCB101-201 Combination Study](https://www.hanchorbio.com/news/hanchorbio-announces-first-confirmed-partial-response-in-colorectal-cancer-cohort-of-ongoing-hcb101-201-combination-study/): HanchorBio announced the first confirmed partial response (PR) in the colorectal cancer (CRC) cohort of its ongoing clinical study evaluating HCB101 in combination with standard-of-care regimens.
- [漢康生技HCB206拓展自體免疫疾病應用，加速推進臨床前關鍵試驗 HanchorBio Expands HCB206 Development into Autoimmune Diseases and Advances IND-Enabling Studies](https://www.hanchorbio.com/news/hanchorbio-expands-hcb206-development-into-autoimmune-diseases-and-advances-ind-enabling-studies/): HanchorBio announced that its internally developed dual-target fusion protein candidate, HCB206, has demonstrated therapeutic potential in preclinical studies across both oncology and autoimmune disease models.
- [漢康-KY上市前業績發表會 5/11登場 FBDB核心平台構築抗癌護城河 瞄準千億美元商機 HanchorBio to Hold May 11 Investor Presentation Ahead of Planned Taiwan Innovation Board Listing](https://www.hanchorbio.com/news/hanchorbio-to-hold-may-11-investor-presentation-ahead-of-planned-taiwan-innovation-board-listing/): HanchorBio announced that it will hold an investor presentation on May 11 ahead of its planned listing on the Taiwan Innovation Board later this month.
- [漢康生技與河北清華發展研究院展開 HCB101 作用機制研究合作 HanchorBio Launches HCB101 Mechanism Collaboration Study with Tsinghua University](https://www.hanchorbio.com/news/hanchorbio-launches-hcb101-mechanism-collaboration-study-with-the-institute-of-tsinghua-university/): HanchorBio started a research collaboration with the Institute of Tsinghua University, Hebei, to further characterize the antitumor mechanisms and translational biology of HCB101, the Company’s AI-guided, structurally engineered, Fc-based fusion protein targeting the CD47-SIRPα axis.
- [漢康生技於台灣癌症聯合年會 (TJCC) 展現次世代合併治療骨幹潛力、腫瘤以外平台拓展與三特異性機制進展 HanchorBio Highlights Next Generation Combination Backbone Potential, Platform Expansion Beyond Oncology, and Tri-specific Mechanistic Progress at TJCC 2026](https://www.hanchorbio.com/news/hanchorbio-highlights-next-generation-combination-backbone-potential-platform-expansion-beyond-oncology-and-tri-specific-mechanistic-progress-at-tjcc-2026/): HanchorBiopresented at the 30th Taiwan Joint Cancer Conference (TJCC 2026). Across a keynote lecture and the company symposium, HanchorBio highlighted clinical and translational data supporting HCB101 as a clinically versatile innate immune backbone and presented a working mechanism framework for its next-generation tri-specific program, HCB301.
- [漢康生技與陽明交大啟動AI賦能藥物研發合作　推進次世代創新生物藥開發 HanchorBio and NYCU Launch AI-Enabled Drug Discovery Collaboration to Advance Next-Generation Biologics](https://www.hanchorbio.com/news/hanchorbio-and-nycu-launch-ai-enabled-drug-discovery-collaboration-to-advance-next-generation-biologics/): HanchorBio started a research collaboration with the College of Engineering Bioscience at National Yang Ming Chiao Tung University (NYCU) to advance AI-enabled biologics discovery.
- [漢康生技與彭博合作 強化藥物開發及全球生物製藥戰略情報能力 HanchorBio Selects Bloomberg to Strengthen its Strategic Intelligence Across Drug Development and Global Biopharma](https://www.hanchorbio.com/news/hanchorbio-selects-bloomberg-to-strengthen-its-strategic-intelligence-across-drug-development-and-global-biopharma/): HanchorBio announced it has selected Bloomberg to support strategic decision-making across portfolio planning, pipeline development, competitive monitoring, business development, and capital markets activities.
- [漢康生技於GBCC 2026發表HCB101聯合療法一線三陰性乳癌早期數據HanchorBio Presents Early Frontline Triple-Negative Breast Cancer Data for HCB101 Combination at GBCC 2026](https://www.hanchorbio.com/news/hanchorbio-presents-early-frontline-triple-negative-breast-cancer-data-for-hcb101-combination-at-gbcc-2026/): HanchorBio announced the first dedicated presentation of HCB101 clinical data from an ongoing study evaluating HCB101 in combination with anti-PD-1 and nab-paclitaxel in patients with advanced triple-negative breast cancer (TNBC) at the Global Breast Cancer Conference 2026 (GBCC 2026) in Seoul, Korea.
- [漢康生技發布 HCB101 頭頸癌數據：單藥展現持久活性，低劑量聯合 PD-1 觀察到完全緩解 HanchorBio Reports Head and Neck Cancer Data for HCB101, Including Durable Monotherapy Activity and Complete Response at Low Dose in Combination with PD-1](https://www.hanchorbio.com/news/hanchorbio-reports-head-and-neck-cancer-data-for-hcb101-including-durable-monotherapy-activity-and-complete-response-at-low-dose-in-combination-with-pd-1/): HanchorBio reported updated clinical observations in head and neck squamous cell carcinoma (HNSCC) across both monotherapy and combination settings for HCB101, its rationally engineered SIRPα-Fc fusion protein functioning as an innate immune checkpoint blockade.
- [漢康生技報告2026年上半年科學溝通成果，並預告第二季將參與多項學術會議HanchorBio Reports Strong H1 2026 Scientific Communication Momentum and Highlights Upcoming Q2 Conference Participation](https://www.hanchorbio.com/news/hanchorbio-reports-strong-h1-2026-scientific-communication-momentum-and-highlights-upcoming-q2-conference-participation/): HanchorBio announced strong scientific communication momentum in the first half of 2026, marked by a broad series of oral, mini-oral, symposium, keynote, and poster presentations across major international scientific meetings. The Company also highlighted its upcoming and recently accepted conference participation in Q2 2026, underscoring continued external visibility across multiple programs, disease areas, and translational settings.
- [漢康生技宣布 HCB101 完成首次 2,000 公升臨床用藥 GMP 批次生產 HanchorBio Announces Successful Completion of First 2,000L GMP Clinical Batch Production of HCB101](https://www.hanchorbio.com/news/hanchorbio-announces-successful-completion-of-first-2000l-gmp-clinical-batch-production-of-hcb101/): HanchorBio's HCB101, one of its core FBDB™ (Fc-Based Designer Biologics) oncology pipeline assets, has successfully completed its first GMP clinical batch production scaled up from a 500L to a 2,000L bioreactor. This production was carried out at WuXi Biologics’ manufacturing facility, covering the full process from Drug Substance (DS) to Drug Product (DP), and achieved all predefined manufacturing objectives.
- [漢康生技受邀參加寬量國際主辦第十九屆 CEO Week 投資論壇 HanchorBio Invited to Participate in the 19th QIC CEO Week](https://www.hanchorbio.com/news/hanchorbio-invited-to-participate-in-the-19th-qic-ceo-week/): HanchorBio has been invited to participate in the 19th QIC CEO Week to meet with international institutional investors in Singapore to share corporate progress and strategic priorities.
- [漢康生技 HCB301 於台灣完成第一期臨床試驗首位患者給藥HanchorBio Doses First Patient in Taiwan in Phase 1 Trial of HCB301](https://www.hanchorbio.com/news/hanchorbio-doses-first-patient-in-taiwan-in-phase-1-trial-of-hcb301/): HanchorBio today announced that the first patient in Taiwan has been dosed in HCB301-101, the Company’s ongoing first-in-human Phase 1 clinical study of HCB301.
- [HanchorBio Signals “Backbone” Potential for HCB101  as SAB Aligns on Gastric Cancer Registrational Path隨著科學顧問委員會（SAB）就胃癌藥證註冊路徑達成共識，漢康生技釋出 HCB101 具備「治療骨幹療法」潛力的明確訊號](https://www.hanchorbio.com/news/hanchorbio-signals-backbone-potential-for-hcb101-as-sab-aligns-on-gastric-cancer-registrational-path/): HanchorBio reported outcomes from its recent Scientific Advisory Board (SAB) meeting, highlighting a shift from platform validation to asset-level positioning and registrational strategy.